Industry analysts peg the peptide therapeutics market at roughly $54B in 2026, growing at a ~6.8% CAGR toward an estimated $85B by 2033 — driven largely by GLP-1 receptor agonists and a broadening pipeline. (Vendor market-research source — verify independently.)